Opportunities in Stem Cell Research and Commercialization: Technology Advances, Regulatory Impact and Key Players : Market Research Report

Opportunities in Stem Cell Research and Commercialization: Technology Advances, Regulatory Impact and Key Players

Published: Mar. 6, 2006 - 207 Pages

Executive Summary: Introduction to stem cells; Regulatory and ethical issues; Technologies and strategies; Market analysis; Adult stem cell programs; Embryonic and fetal stem cell programs; Patents in stem cell research; Trends and opportunities
Chapter 1 Introduction to stem cells: Summary; Introduction; Major milestones in stem cell research; Characteristics of embryonic and adult stem cells; Current uses of stem cells; Potential uses of stem cells
Chapter 2 Regulatory and ethical issues: Summary; Introduction; Regulation of cell and tissue therapies (USA); Ethical issues in embryonic stem cell research; Global embryonic stem cell policies
Chapter 3 Technologies and strategies: Summary; Introduction; Culture of adult stem cells; Examples of adult stem cell cultures; Culture of mouse ESCs; Culture of human ESCs; Tissue engineering
Chapter 4 Market analysis: Summary; Introduction; The regulation of cellular therapy; Human embryonic stem cells (hESCs); Human mesenchymal stem cells (MSCs); Human hematopoietic stem cells (HSCs); Stem cell mobilization; Stem cell expansion; Stem cell therapy and tissue engineering products; Commercial applications; Embryonic and fetal stem cell programs; Potential markets; Overview of stem cell market forecasts; The stem cell market, 2005-2010; Stem cell competitive landscape; Chapter 5 Adult stem cell programs; Summary; Introduction; Hematopoietic stem cell (HSC) transplantation; Mesenchymal stem cells for GvHD; In vivo stem cell activation; Stem cells for tissue repair/regeneration; Stem cells for drug testing applications
Chapter 6 Embryonic and fetal stem cell programs: Summary; Introduction; Human embryonic stem cell (hESC) lines; Harnessing the power of ESCs; Human fetal stem cell therapies
Chapter 7 Patents in stem cell research: Summary; Introduction; Patent systems in Europe and the US; Patenting of stem cells; Survey of US stem cell patents
Chapter 8 Trends and opportunities: Summary; Slow beginnings, big promise; Ensuring a strong proprietary position; Exploiting accessible sources of adult stem cells; Regenerative medicine takes shape; Commercializing stem cells for drug screening; Embracing embryonic stem cell research
Chapter 9 Appendix: Specialist stem cell companies; Companies with adult stem cell programs; Companies with fetal and embryonic stem cell programs; Cord blood banks around the world; The top 30 stem cell patent citations; Abbreviations; Index
List of Figures: Figure 1.1: History of stem cell research; Figure 4.2: Commercial focus of 106 stem cell companies by type of stem cell program; Figure 4.3: Geographic location of 106 specialized stem cell companies; Figure 4.4: Ownership status of 106 specialized stem cell companies; Figure 4.5: Cord blood banks by region; Figure 7.6: US stem cell patents, filed 1980-2005; Figure 7.7: Patent activity analysis for types of Stem cells, filed 1980-2005; Figure 7.8: Top 30 US stem cell patents: types of stem cell and technology areas; Figure 7.9: Top 30 US stem cell patents: therapy area; Figure 7.10: Top 30 US stem cell patents by FCN, filed 1980-2005
List of Tables: Table 4.1: Potential US patient populations for cell-based therapies, 2005; Table 4.2: Annual direct expenditures in the US for selected diseases, 2005; Table 4.3: Stem cell market forecasts by technology and product type, 2005-2010; Table 4.4: Stem cell market forecasts by region, 2005-2010; Table 7.5: Top 30 stem cell patents by forward citations (US filings), 1980-2005; Table 7.6: Top 30 assignees for US stem cell patents (US filings 1980-2005); Table 8.7: Specialist companies with proprietary adult stem cells or proprietary technogies; Table 8.8: Specialist companies developing autologous and allogeneic therapies for tissue; regeneration/repair; Table 9.9: 106 specialist stem cell companies; Table 9.10: 106 specialist stem cell companies (cont.); Table 9.11: Commercial exploitation of adult stem cells for blood cancers and other blood diseases; Table 9.12: Commercial exploitation of adult stem cells for tissue repair/regeneration; Table 9.13: Commercial exploitation of adult stem cells for tissue repair/regeneration (cont.); Table 9.14: Commercial exploitation of adult stem cells: miscellaneous research/services; Table 9.15: Programs utilizing human fetal stem cells; Table 9.16: Programs utilizing human embryonic stem cells; Table 9.17: Programs utilizing animal embryonic stem cells; Table 9.18: Cord Blood Banks in the US and Canada; Table 9.19: Cord Blood Banks in Mexico, Central and South America; Table 9.20: Cord Blood Banks in the UK and rest of Europe; Table 9.21: Cord Blood Banks in the Middle East, Asia, Africa, Australia and New Zealand

Abstract

Stem cell transplants are routinely used to treat patients with cancers and other disorders of the blood and the immune system and may hold the key to repairing or replacing tissue cells damaged in many devastating diseases. Thus, proven and potential clinical benefit underpins the vast interest in stem cell research. Stem cells have both the capacity to self-renew (by cell division) and differentiate into mature, specialized cells. Differentiation describes a process of development with an increase in the level of organisation or complexity of a cell, accompanied with a more specialized function. During differentiation, certain genes become activated and other genes become inactivated in an intricately regulated fashion. As a result, a differentiated cell develops specific structures and performs certain functions.

Key features:

Growth forecasts for stem cell market sub-sectors to 2010.
An examination of proprietary technologies and company strategies shaping the market for adult, embryonic and fetal stem cell products.
Assessment of the therapeutic potential of human stem cells for tissue repair and regeneration.
Analysis of global regulatory issues which are dictating where and how embryonic stem cell research is being done.

Key findings:

The market for stem cell products and services (including cytokines) is forecast to grow almost three-fold from $24.6 billion in 2005 to $68.9 billion in 2010.
During the years 1980-2005, over 2,000 US patents claiming stem cell technologies and applications relevant to healthcare were published; the annual publication rate accelerated sharply in 2002.
The majority of adult stem cell R&D is conducted in the US, while most embryonic stem cell research is conducted outside the US due to a restrictive legislative environment.
In 2005, the first commercial product containing adult stem cells was launched in the US - Osiris Therapeutics Osteocel.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/15/2012 - 32

Opportunities in Stem Cell Research and Commercialization: Technology Advances, Regulatory Impact and Key Players

Table of Contents

Abstract